Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...

Q4 2024 Earnings Call Transcript February 28, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Full Year 2024 Results Key Financial Results Revenue: US$58.8m (up 32% ...

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological ...

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

TD Cowen analyst Brendan Smith maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report) today. The company’s shares ...

Reports Q4 revenue $4.55M vs. $10.9M last year. “In 2024, Recursion made a transformative leap with the largest TechBio merger in history, ...

Recursion Pharmaceuticals shares last traded at $7.25, with a volume of 11,698,781 shares. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates ...

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...